NASDAQ:ESPR - Esperion Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$52.33 +1.38 (+2.71 %)
(As of 05/26/2019 01:15 PM ET)
Previous Close$52.33
Today's Range$50.8850 - $52.44
52-Week Range$35.80 - $60.99
Volume196,851 shs
Average Volume610,809 shs
Market Capitalization$1.41 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.11
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ESPR
CUSIPN/A
Phone734-887-3903

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.50 per share

Profitability

Net Income$-201,810,000.00

Miscellaneous

Employees76
Market Cap$1.41 billion
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics Inc (NASDAQ:ESPR) posted its earnings results on Wednesday, May, 8th. The biopharmaceutical company reported $3.07 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.64 by $2.43. The biopharmaceutical company had revenue of $145.42 million for the quarter, compared to analyst estimates of $69.35 million. During the same quarter in the previous year, the firm posted ($1.73) EPS. View Esperion Therapeutics' Earnings History.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Esperion Therapeutics.

What price target have analysts set for ESPR?

11 equities research analysts have issued 1-year price targets for Esperion Therapeutics' stock. Their predictions range from $47.00 to $114.00. On average, they expect Esperion Therapeutics' share price to reach $77.90 in the next twelve months. This suggests a possible upside of 48.9% from the stock's current price. View Analyst Price Targets for Esperion Therapeutics.

What is the consensus analysts' recommendation for Esperion Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 4 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Esperion Therapeutics.

What are Wall Street analysts saying about Esperion Therapeutics stock?

Here are some recent quotes from research analysts about Esperion Therapeutics stock:
  • 1. Chardan Capital analysts commented, "We find the relevant statistical analyses in the NEJM publications roughly consistent with those of our consulted biostatisticians and still see the following open issues as unresolved:." (3/14/2019)
  • 2. Northland Securities analysts commented, "We anticipate a clear path to approval in both jurisdictions, w/ commercialization in 1Q2020 (US) and 2Q2020 (EU), respectively. Esperion reported 4Q EPS of ($2.24) vs. the consensus of ($1.39), reflecting higher R&D associated w/ regulatory progression of bempedoic acid and various clinical trials, including its ~12,600 subject CLEAR Outcomes trial. Considering year-end cash equivalents of ~ $126MM, plus receipt of $150MM upfront payment in Europe (DSE) related to its EU partnership, we approximate current cash balances to be in the $250MM vicinity. The Co. anticipates net cash used from operations in 2019 to approximate $25MM-to-$35MM, reflecting the aforementioned receipt of the $150MM upfront payment from R&D cash expenditures, and $60MM-to- $65MM SG&A cash expenditures ." (3/1/2019)
  • 3. According to Zacks Investment Research, "Esperion has no approved products in its portfolio. It focuses on developing new oral therapies for LDL-C lowering indications. The company’s pipeline products, bempedoic acid pill and bempedoic acid/Zetia combination pill achieved significant reduction in elevated bad cholesterol levels in hypercholesterolemia patients. The targeted area represents a significant opportunity. Esperion plans to file regulatory applications for both the candidates in the United States and Europe in the first half of 2019. However, Esperion neither has a marketed product nor a collaboration agreement to generate funds to support development and commercialization of its pipeline candidates. Esperion's share have outperformed the industry in past six months. Loss estimates have been stable ahead of Q4 earnings. Esperion has a mixed record of earnings surprise in the recent quarters." (2/8/2019)

Has Esperion Therapeutics been receiving favorable news coverage?

Media stories about ESPR stock have been trending negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Esperion Therapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the stock's share price in the next few days.

Who are some of Esperion Therapeutics' key competitors?

What other stocks do shareholders of Esperion Therapeutics own?

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the folowing people:
  • Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 58)
  • Dr. Narendra D. Lalwani, Exec. VP of R&D (Age 66)
  • Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 37)
  • Mr. Alexander Duke Schwartz, Sr. Director of Investor Relations
  • Ms. Marianne Andreach, Sr. VP

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Pentwater Capital Management LP (9.20%), BlackRock Inc. (6.90%), Wasatch Advisors Inc. (2.37%), FMR LLC (2.15%), Rhenman & Partners Asset Management AB (1.79%) and Goldman Sachs Group Inc. (1.73%). Company insiders that own Esperion Therapeutics stock include Boxer Capital, Llc, Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.

Which institutional investors are selling Esperion Therapeutics stock?

ESPR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, JPMorgan Chase & Co., Hsbc Holdings PLC, BlackRock Inc., Rothschild & Co. Asset Management US Inc., Natixis and US Bancorp DE. Company insiders that have sold Esperion Therapeutics company stock in the last year include Boxer Capital, Llc, Nicole Vitullo, Richard Bartram and Roger S Newton. View Insider Buying and Selling for Esperion Therapeutics.

Which institutional investors are buying Esperion Therapeutics stock?

ESPR stock was acquired by a variety of institutional investors in the last quarter, including Pentwater Capital Management LP, Renaissance Technologies LLC, Spark Investment Management LLC, Goldman Sachs Group Inc., Rhenman & Partners Asset Management AB, Wasatch Advisors Inc., Man Group plc and Pictet Asset Management Ltd.. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech and Timothy M Mayleben. View Insider Buying and Selling for Esperion Therapeutics.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $52.33.

How big of a company is Esperion Therapeutics?

Esperion Therapeutics has a market capitalization of $1.41 billion. The biopharmaceutical company earns $-201,810,000.00 in net income (profit) each year or ($7.54) on an earnings per share basis. Esperion Therapeutics employs 76 workers across the globe.

What is Esperion Therapeutics' official website?

The official website for Esperion Therapeutics is http://www.esperion.com/.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]


MarketBeat Community Rating for Esperion Therapeutics (NASDAQ ESPR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  470 (Vote Outperform)
Underperform Votes:  384 (Vote Underperform)
Total Votes:  854
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/26/2019 by MarketBeat.com Staff

Featured Article: Stop Order

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel